tbuckley/cabot-search huggingface dataset:
S72 Improving lung cancer survival in England evidenced through multiple data sources: Abstract S72 Table 1
Authors: P Beckett, I Woolhouse, S Walters, S Benitez-Majano, P Muller, D West, S McPhail, J Broggio, MD Peake
Journal: Thorax (2015)

<h3>Introduction</h3> We have collated data from several sources to demonstrate that efforts made over the last 10 years to use data to drive service improvement and improved patient outcomes for UK patients with lung cancer have been successful. <h3>Methods</h3> We used data submitted to the National Lung Cancer Audit (NLCA), National Cancer Registration Service (NCRS), Office for National Statistics (ONS) and Society of Cardiothoracic Surgeons (SCTS) from 1995–2013. We calculated numbers and proportions undergoing surgery, case-mix adjusted hazard ratios for death, and actual and predicted (using hybrid analyses) 1-year and 5-year survival for lung cancer patients in England. An international comparison has been made using data from the CONCORD-2 study. <h3>Results</h3> In the NLCA, the proportion of NSCLC patients undergoing resection has risen from 14% (2005) to 23% (2013). Over this period, annual primary lung cancer resections have risen from 3,220 to 6,713. NLCA data, adjusted for age, sex, stage and PS, indicates a gradually falling hazard ratio for death (2013 HR 0.87, 95% CI 0.85–0.89 compared to 2008). ONS data demonstrates a gradual improvement in both 1 yr and 5 yr, and mirrors the increase in the number of resections carried out over the lifetime of the NLCA. Comparison of 1YS with other countries suggests that England has passed the survival measured in Denmark in 2004–07 (35%), but still lags behind Canada (42%) and Sweden (46%). In another analysis using NCRS data, comparing stage-specific 1 yr survival in England in 2004–07 and 2012, improvements are most marked in patients with early stage disease. <h3>Conclusion</h3> Whilst many changes have taken place in the management of lung cancer over the last 10 years, the close temporal association between the date of the first NLCA report (2005), the numbers of resections carried out and the significant improvements in 1 and 5 yr survival (weighted towards earlier stages) and mortality we report here, would strongly suggest that the NLCA has been successful in its aim to improve standards of care and outcomes for patients. These improvements in survival bring England close to parity with other westernised countries, though there is still more work to do.
Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B
Authors: Han Ah Lee, Yeon Seok Seo, Seung Woon Park, Sang Jung Park, Tae Hyung Kim, Sang Jun Suh, Young Kul Jung, Ji Hoon Kim, Hyunggin An, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun, Soon Ho Um
Journal: Clinical and Molecular Hepatology (2016)

Clear indicators for stopping antiviral therapy in chronic hepatitis B (CHB) patients are not yet available. Since the level of hepatitis B surface antigen (HBsAg) is correlated with covalently closed circular DNA, the HBsAg titer might be a good indicator of the off-treatment response. This study aimed to determine the relationship between the HBsAg titer and the entecavir (ETV) off-treatment response. This study analyzed 44 consecutive CHB patients (age, 44.6±11.4 years, mean±SD; men, 63.6%; positive hepatitis B envelope antigen (HBeAg) at baseline, 56.8%; HBV DNA level, 6.8±1.3 log10 IU/mL) treated with ETV for a sufficient duration and in whom treatment was discontinued after HBsAg levels were measured. A virological relapse was defined as an increase in serum HBV DNA level of >2000 IU/mL, and a clinical relapse was defined as a virological relapse with a biochemical flare, defined as an increase in the serum alanine aminotransferase level of >2 × upper limit of normal. After stopping ETV, virological relapse and clinical relapse were observed in 32 and 24 patients, respectively, during 20.8±19.9 months of follow-up. The cumulative incidence rates of virological relapse were 36.2% and 66.2%, respectively, at 6 and 12 months, and those of clinical relapse were 14.3% and 42.3%. The off-treatment HBsAg level was an independent factor associated with clinical relapse (hazard ratio, 2.251; 95% confidence interval, 1.076-4.706; P=0.031). When patients were grouped according to off-treatment HBsAg levels, clinical relapse did not occur in patients with an off-treatment HBsAg level of ≤2 log10 IU/mL (n=5), while the incidence rates of clinical relapse at 12 months after off-treatment were 28.4% and 55.7% in patients with off-treatment HBsAg levels of >2 and ≤3 log10 IU/mL (n=11) and >3 log10 IU/mL (n=28), respectively. The off-treatment HBsAg level is closely related to clinical relapse after treatment cessation. A serum HBsAg level of <2 log10 IU/mL is an excellent predictor of a sustained off-treatment response in CHB patients who have received ETV for a sufficient duration.
High Response Rates To Crizotinib In Advanced, Chemoresistant ALK+ Lymphoma Patients
Authors: Sara Redaelli, Francesca Farina, Alessandra Stasia, Monica Ceccon, Luca Mologni, Cristina Messa, Luca Guerra, Giovanni Giudici, Elena Sala, Lara Mussolin, Dries Deeren, Michael H. King, Michael Steurer, Rainer Ordemann, Amos Cohen, Matthias Grube, Lea Bernard, Gianpaolo Chiriano, Rocco Piazza, Carlo Gambacorti-Passerini
Journal: Blood (2013)
The influence of polymorphisms in cytokine genes on pain and response to analgesia in lung cancer patients receiving palliative treatment
Authors: C. C. Reyes-Gibby, B. E. El Osta, M. Spitz, H. A. Parsons, R. Kurzrock, S. Shete, E. Bruera
Journal: Journal of Clinical Oncology (2008)

9503 Background: We reported cytokine gene polymorphisms as a significant factor for severe pain at time of registration in 446 White patients newly diagnosed with non-small cell lung cancer. This follow-up study explores the extent to which cytokine gene variants could explain variability in self-reported pain and analgesic response among those patients (n=140) subsequently referred to palliative care specialists for pain treatment and control. Methods: Pain severity (0=no pain; 10-worst pain) was assessed at initial consultation and at first follow- up visit. Total dose of opioids at the time of first-follow up visit was converted to an equivalent dose of parenteral morphine. We genotyped single nucleotide polymorphisms in tumor necrosis factor-alpha (TNF α-308 G/A), interleukin (IL) -6 - 174G/C, and IL-8 -251T/A genes. Results: Forty-one percent (57/140) of the patients reported severe pain (score >7/10) at initial consultation (mean=5.5; median=6; mode=7), which significantly decreased to 25% (mean= 4; median=4; mode=2) at first follow-up visit (McNemar=P<0.01). Mean Morphine Equivalent Daily Dose (MEDD) obtained during the first follow-up visit was 89mg/24h (SD=119) and median was 50 mg/24h. Polymorphisms in TNF and IL6 were significantly associated with pain severity (TNF α-308 G/G=4.12; G/A=5.38; A/A=5.50; p=0.04) and with MEDD (IL-6 -174G/G=69.61; G/C=93.6; C/C=181.67; p=0.004), respectively. Adjusting for demographic and clinical variables, the TNF-308 G/A variant (b=1.309; p=0.036) remained significantly associated with pain severity. In terms of opioid requirements for pain relief, patients carrying the IL6–174C/C genotypes required 4.7 times higher dose [Odds Ratio=4.7; 95%CI=1.2; 15.0] relative to G/G and G/C genotypes. Conclusions: This analysis provides preliminary evidence of the influence of cytokine genes on pain and response to analgesia in lung cancer patients. Additional studies are needed to validate our findings. The long-term application is to tailored pain therapies. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration AstraZeneca Oncology, Exelixis, Merck, Novartis
Advances, Pauses, and Future Opportunity for the Prevention of Venous Thromboembolism in the Trauma Population
Authors: Christopher R. Ramos, Luke P. Brewster
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Transcatheter or surgical aortic valve replacement for patients with severe, symptomatic, aortic stenosis at low to intermediate surgical risk: a clinical practice guideline
Authors: Per O Vandvik, Catherine M Otto, Reed A Siemieniuk, Rodrigo Bagur, Gordon H Guyatt, Lyubov Lytvyn, Richard Whitlock, Trond Vartdal, David Brieger, Bert Aertgeerts, Susanna Price, Farid Foroutan, Michael Shapiro, Ray Mertz, Frederick A. Spencer
Journal: BMJ (2016)

In patients with symptomatic severe aortic stenosis but at lower risk of perioperative death, how do minimally invasive techniques compare with open surgery? Prompted by a recent trial, an expert panel produced these recommendations based on three linked rapid systematic reviews
Superior Outcomes Associated with Complete Response: Analysis of the Phase III VISTA Study of Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone
Authors: Jean-Luc Harousseau, Antonio Palumbo, Paul Richardson, Rudolf Schlag, Meletios A Dimopoulos, Ofer Shpilberg, Martin H Kropff, Michel Delforge, Rik Schots, Michele Cavo, Anatoly Golenkov, Mieczyslaw Komarnicki, Maria-Victoria Mateos, Andrew Cakana, Kevin Liu, William Deraedt, Helgi van de Velde, Jesus F San Miguel
Journal: Blood (2008)
Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study
Authors: Macarius M Donneyong, Katsiaryna Bykov, Pauline Bosco-Levy, Yaa-Hui Dong, Raisa Levin, Joshua J Gagne
Journal: BMJ (2016)

<b>Objective</b>&nbsp;To compare differences in mortality between women concomitantly treated with tamoxifen and selective serotonin reuptake inhibitors (SSRIs) that are potent inhibitors of the cytochrome-P450 2D6 enzyme (CYP2D6) versus tamoxifen and other SSRIs. <b>Design</b>&nbsp;Population based cohort study. <b>Setting</b>&nbsp;Five US databases covering individuals enrolled in private and public health insurance programs from 1995 to 2013. <b>Participants</b>&nbsp;Two cohorts of women who started taking tamoxifen. In cohort 1, women started taking an SSRI during tamoxifen treatment. In cohort 2, women were already taking an SSRI when they started taking tamoxifen. <b>Main outcome measures</b>&nbsp;All cause mortality in each cohort in women taking SSRIs that are potent inhibitors of CYP2D6 (paroxetine, fluoxetine) versus other SSRIs. Propensity scores were used to match exposure groups in a variable ratio fashion. Results were measured separately for each cohort and combined hazard ratios calculated from Cox regression models across the two cohorts with random effects meta-analysis. <b>Results</b>&nbsp;There were 6067 and 8465 new users of tamoxifen in cohorts 1 and 2, respectively. Mean age was 55. A total of 991 and 1014 deaths occurred in cohorts 1 and 2 during a median follow-up of 2.2 (interquartile range 0.9-4.5) and 2.0 (0.8-3.9) years, respectively. The pooled hazard ratio for death for potent inhibitors (rate 58.6/1000 person years) compared with other SSRIs (rate 57.9/1000 person years) across cohorts 1 and 2 was 0.96 (95% confidence interval 0.88 to 1.06). Results were consistent across sensitivity analyses. <b>Conclusion</b>&nbsp;Concomitant use of tamoxifen and potent CYP2D6 inhibiting SSRIs versus other SSRIs was not associated with an increased risk of death.
Strong and Rapidly Self‐Healing Hydrogels: Potential Hemostatic Materials
Authors: Weijuan Huang, Yixiang Wang, Yun Chen, Yanteng Zhao, Qiang Zhang, Xiang Zheng, Lingyun Chen, Lina Zhang
Journal: Advanced Healthcare Materials (2016)

Benzaldehyde-terminated telechelic four-armed polyethylene glycol (PEG-BA) is synthesized and cross-linked with carboxymethyl chitosan (CMC) to form dynamic hydrogels with strong mechanical performance. The gelation temperature and time, mechanical performance, and self-healing behaviors are systematically investigated. The hydrogels have good storage modulus up to 3162.06 ± 21.06 Pa, comparable to conventional bulk hydrogels. The separated alternate hydrogel lines connect together to become an integrated hydrogel film after 5 min at room temperature without any external intervention. This is due to the dynamic equilibrium between the Schiff base linkages and the aldehyde groups of PEG-BA and amine groups on CMC backbone. The hydrogel shows excellent cytocompatibility and the cell viability is as high as 90.7 ± 6.8% after 2 d 3D encapsulation in the hydrogel. In vivo tests indicate that the hydrogels can effectively stop bleeding when the hydrogel is directly injected into a rabbit liver incision. The total blood loss is reduced from 0.65 ± 0.10 g to 0.29 ± 0.11 g, and the hemostasis time is decreased from 167 ± 21 s to 120 ± 10 s, when compared to a gauze treatment with physical compression. These self-healing hydrogels have potential to be used as a novel hemostatic material.
Novel Anti-CD37 Small Modular Immunopharmaceutical (SMIP) Induces B-Cell-Specific, Caspase-Independent Apoptosis in Human CLL Cells.
Authors: Xiaobin B. Zhao, Sabyasachi Biswas, Andrew Mone, Jeffrey Ledbetter, Martha Hayden Ledbetter, Laura Grosmaire, Erik Espling, Carolyn Cheney, Donn Young, Robert J. Lee, Natarajan Muthusamy, John C. Byrd
Journal: Blood (2004)
LITAF, a BCL6 Target Gene, Regulates Autophagia in B Cells and Is Essential for T-Cell Dependent Humoral Responses
Authors: Cristina Bertolo, Raquel Malumbres, Ainara Sagardoy, Eloy F Robles, Jose I Martinez-Ferrandis, Sergio Roa, Izidore S Lossos, Xavier Sagaert, Ari Melnick, Salomon Amar, Jose A Martinez-Climent
Journal: Blood (2011)
High Molecular Weight Kininogen Fragments Stimulate the Secretion of Interleukin-1β through the NFκ B, JNK and p38 MAP Kinase Signaling Pathways in Monocytes.
Authors: Mohammad M. Khan, Harland N. Bradford, Irma Isordia-Salas, Yuchuan Liu, Yi Wu, Ricardo G. Espinola, Berhane Ghebrehiwet, Robert W. Colman
Journal: Blood (2006)
Cytogenetics of 125 Untreated Patients with Binet Stages B or C B-CLL. Preliminary Results of a Multicentric Study from the French Cooperative Study Group on CLL.
Authors: Florence Nguyen-Khac, Nathalie Leporrier, Isabelle Radford-Weiss, Christine Lefebvre, Christian Bastard, Anne Hagemeijer, Isabelle Tigaud, Marc Debraekeleer, Michel Lessard, Frederic Davi, Claude Lesty, Leporrier Michel, Helene Merle-Beral, Sophie D. Raynaud, Laurent Sutton
Journal: Blood (2005)
The in vivo Transcriptional Response Towards Epigenetic Modulating Agents in Multiple Myeloma
Authors: Ken Maes, Eva De Smedt, Kassambara Alboukadel, Dirk Hose, Anja Seckinger, Els Van Valckenborgh, Eline Menu, Bernard Klein, Karin Vanderkerken, Jerome Moreaux, Elke De Bruyne
Journal: Blood (2014)
Use of chemotherapy for advanced non-small cell lung cancer in a contemporary and diverse patient population.
Authors: D. W. Rasco, J. Yan, J. Dowell, D. E. Gerber
Journal: Journal of Clinical Oncology (2010)

e18006 Background: Despite evidence that chemotherapy prolongs survival, without substantially impairing quality of life, for patients with advanced non-small cell lung cancer (NSCLC), population-based studies have shown that only 20-30% of these patients receive systemic therapy. However, these studies have relied on Medicare-based data—hence including only patients aged ≥ 65 years. We therefore determined the use of chemotherapy in a contemporary NSCLC population encompassing all patient ages. Methods: We performed a retrospective analysis of consecutive patients diagnosed with stage IV NSCLC from 2000 to 2007 at the University of Texas Southwestern Medical Center. Demographic, tumor, and treatment data were obtained from hospital tumor registries and individual patient records. The association between these variables was assessed using univariate analysis, multivariate logistic regression, and survival analysis. Results: A total of 718 patients met criteria for analysis. Mean age was 64 years, 42% were female, and 45% were non-Hispanic white. 353 patients (49%) received chemotherapy. In univariate analysis, receipt of chemotherapy was associated with age (53% for age < 65 years vs. 41% for age ≥ 65 years; p = 0.003) and insurance type (40% for no insurance vs 60% for private insurance; p = 0.0002), but was not associated with gender, race, or year of diagnosis. In a multivariate model, age (OR [< 65 years vs ≥ 65 years] 1.96; 95% CI, 1.26- 3.06; p = 0.003) and insurance type (OR [no insurance vs private insurance] 0.44; 95% CI 0.30-0.64; p < 0.0001) remained associated with receipt of chemotherapy. In multivariate analysis, gender (HR [female vs male] 0.85, 95% CI, 0.72-0.99; p = 0.04) and receipt of chemotherapy (HR [no chemo vs. chemo] 2.81; 95% CI, 2.38-3.31; p < 0.0001) were associated with overall survival. Conclusions: In a contemporary population representing the full age range of patients with stage IV NSCLC, chemotherapy was administered to nearly half of all patients—substantially more than in previous studies. Younger patients and insured patients were more likely to receive chemotherapy. Receipt of chemotherapy was associated with longer survival. These findings warrant further investigation. No significant financial relationships to disclose.
Response to Comment on American Diabetes Association. Approaches to Glycemic Treatment. Sec. 7. In <i>Standards of Medical Care in Diabetes—2016</i>. Diabetes Care 2016;39(Suppl. 1):S52–S59
Authors: William H. Herman, Rita R. Kalyani, Deborah J. Wexler, David R. Matthews, Silvio E. Inzucchi
Journal: Diabetes Care (2016)
Arming An Anti-CD38, Myeloma-Targeting Antibody With An Attenuated IFNα Provides &gt;10,000-Fold Enhanced Tumor-Specific Activity Compared To Native IFNα
Authors: Sarah L. Pogue, Tetsuya Taura, Mingying Bi, Glen E. Mikesell, Yong Yun, Angela Sho, Eric Sanchez, Haiming Chen, James R. Berenson, David S. Wilson
Journal: Blood (2013)
The role of virus-specific CD8+cells in liver damage and viral control during persistent hepatitis B virus infection
Authors: M K Maini, C Boni, K Lee, Larrubia, S Reignat, G S Ogg, J Herberg, R Gilson, A Alisa, R Williams, D Vergani, N Naoumov, C Ferrari, A Bertoletti
Journal: Journal of Hepatology (2000)
Feasibility of geriatric assessment for older adults with acute myeloid leukemia (AML) receiving intensive chemotherapy on a cooperative group trial: CALGB 361006 (Alliance).
Authors: Heidi D. Klepin, Ellen K. Ritchie, Ben L. Sanford, Guido Marcucci, Weiqiang Zhao, Susan Michelle Geyer, Karla V. Ballman, Bayard L. Powell, Maria R. Baer, Wendy Stock, Harvey Jay Cohen, Richard M. Stone, Richard A. Larson, Geoffrey L. Uy
Journal: Journal of Clinical Oncology (2014)

7102 Background: Geriatric assessment (GA) may improve characterization of fitness for intensive AML therapy and identify vulnerabilities to target for improved treatment tolerance. Feasibility of performing GA prior to intensive induction has not been demonstrated in a multi-site cooperative group trial. Methods: CALGB 361006 was a companion study offered to patients (pts) enrolled on CALGB 11001, a phase 2 trial of adults ≥60 years of age with newly diagnosed FLT3 mutated AML testing the efficacy of adding sorafenib to intensive therapy. On CALGB 361006, a GA was administered prior to induction therapy and prior to post-remission therapy. The GA is divided into items completed by a health care professional (HCP) (comorbidity index, performance status, Timed up and go test, cognition screen, nutrition screen) and a self-administered pt questionnaire (physical function, health, falls, comorbidity, medications, mood, social activities/support). Prior to enrollment, phone training on GA procedures was conducted with site research teams. Feasibility outcomes include recruitment, implementation (time to completion, difficulty with administration, percent of pts requiring assistance) and satisfaction with the assessment. Results: Among 54 eligible pts, 43 (80%) enrolled on the GA companion (median age 67.6 years, 44% female). Of these, the HCP assessment and pt questionnaire were completed and available for 86% and 88% at baseline respectively. Median time to complete the entire GA was 30 minutes (range 5-65); median time for each component was 10 and 21 minutes for HCPs and pts respectively. Among HCPs, 100% reported no difficulty completing the baseline assessment. Among pts, 84% reported no difficulty understanding any question; 78% required no assistance with completion; 95% reported no upsetting questions. The majority of pts (82%) were satisfied with assessment length. Conclusions: Recruitment to and implementation of a primarily self-administered GA is feasible prior to intensive induction for older adults with AML in the multi-site cooperative group setting. Next steps will explore the predictive utility of GA on toxicity.
Impact of early palliative care on caregivers of patients with advanced cancer: cluster randomised trial
Authors: J. McDonald, N. Swami, B. Hannon, C. Lo, A. Pope, A. Oza, N. Leighl, M.K. Krzyzanowska, G. Rodin, L.W. Le, C. Zimmermann
Journal: Annals of Oncology (2016)